Beida pharmaceutical: clinical trial of batirizumab injection in the treatment of cervical cancer approved
Beida pharmaceutical announced that the company and Agnus jointly declared the evaluation of clinical trials of balstilimab injection (PD-1 antibody) alone or combined with zalifrelimab injection (CTLA-4 antibody) in the treatment of advanced cervical cancer, which has been approved by nmpa.
This text is a result of machine translation.
Related companies：
In-depth
Financials, Communication
Chinese Education Goes Global: Capturing a Trillion-Dollar Market
A TikTok filter challenge called "Mandarin Fruit Voices" has gone viral. Essentially a straightforward Mandarin learning game with crude animations, minimalist gameplay, and fruit-based pronunciation exercises drawn from early childhood education materials, it has nonetheless captivated international users. For those who once struggled with English, the long-held dream of a world united by Chinese now appears increasingly within reach.
Mar 27, 2025 06:55 PM
Dec 11, 2023 08:49 PM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Briefing Nov 29, 2021 07:59 PM
· Healthcare
Boten Co., Ltd.: direnavir API has passed who PQ certification
Briefing Aug 31, 2021 08:59 PM
TECO shares: obtained an invention patent certificate
Consumer Staples · Analysis
China’s “Dark Cuisine” and Southeast Asia’s Wealth Code
In recent years, China’s food and beverage industry has sped up its overseas expansion, with Southeast Asia as a key market. Among the top destinations, Malaysia and Indonesia stand out for their large populations, active economies, and cultural diversity, attracting many Chinese brands.
Apr 07, 2025 03:46 PM
Financials
Temasek-Backed Asset Manager Expands to Abu Dhabi, Strengthening Global Footprint
Apr 02, 2025 06:31 PM
Briefing Jul 07, 2021 03:24 PM
· Healthcare
The first bank of China fund to release its second Quarterly Report
Briefing Dec 11, 2020 08:17 PM
· Healthcare
Beida pharmaceutical: the three shareholders intend to reduce the shares of the company no more than 2.31%
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
China’s “Dark Cuisine” and Southeast Asia’s Wealth Code
Apr 07, 2025 03:46 PM
Insight
In-depth
Insight
In-depth
